NCT03071575View on ClinicalTrials.gov

Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age

PHASE4CompletedINTERVENTIONAL
Enrollment

637

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

March 18, 2018

Study Completion Date

March 18, 2018

Conditions
MeaslesRubellaRubella Syndrome, Congenital
Interventions
BIOLOGICAL

Measles-rubella (MR) vaccine at 6 months of age

Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)

BIOLOGICAL

Measles-rubella (MR) vaccine at 9 months of age

Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)

Trial Locations (1)

Unknown

Icddr,B, Chāndpur

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

collaborator

Ministry of Health and Family Welfare, Bangladesh

UNKNOWN

lead

Centers for Disease Control and Prevention

FED

NCT03071575 - Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age | Biotech Hunter | Biotech Hunter